EGFR突變肺癌：同步放化療後的泰格莎治療選擇 EGFR-Mutant Lung Cancer: Osimertinib After Concurrent Chemoradiotherapy

這段影片將探討EGFR突變肺癌患者在接受同步放化療後，考慮使用Osimertinib（奧希替尼）治療的選擇。觀眾將了解到這種治療策略的背景、臨床研究結果及其潛在的益處與風險。

This video will discuss the option of using Osimertinib (Tagrisso) for EGFR-mutant lung cancer patients after concurrent chemoradiotherapy. Viewers will learn about the background of this treatment strategy, clinical research outcomes, and its potential benefits and risks.